Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm, Open-Label, Multi-Center, Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Single-Arm, Open-Label, Multi-Center, Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linperlisib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Intestinal cancer; Liver cancer; Lung cancer; Malignant thymoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Shanghai Yingli Pharmaceutical

Most Recent Events

  • 08 Jun 2021 Results (Data cut off 28 Dec 2020, n=70) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
  • 03 Jun 2021 Results presented in the Yingli Pharma Media Release.
  • 03 Jun 2021 According to a Yingli Pharma media release, data from this trial will be presented at the at the American Society for Clinical Oncology 2021 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top